IP Library Granted Patent US 8,726,906
Granted Patent B2
US 8,726,906 · App. 13/684,546 · Granted May 20, 2014

Methods and devices for conduit occlusion

Inventors: Kathy Lee-Sepsick (Suwanee, GA); Max S. Azevedo (Alpharetta, GA); Daniel S. Currie (Cumming, GA)
Assignee: Femasys Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,726,906
App. No.
13/684,546
Granted
May 20, 2014
Kind
B2
Abstract

The present invention comprises systems, methods and devices for the delivery of compositions for occluding or of elements for opening conduits. The implantable occlusive material may be delivered pre-formed or in situ cured and, may be a resorbable or degradable material that supports tissue ingrowth or wound healing or a similar response that replaces the cured occlusive material leaving little or no original occlusive material in place. The delivery system is positioned to allow for placement of the occlusive material into the body conduit. Use of delivery systems, methods and devices for re-opening an occluded body conduit are also included.

Claims (30)

1. A method for occluding one fallopian tube in a human or animal body, comprising,

(a) providing a delivery system that delivers an effective amount of an occlusive material composition, wherein the delivery system comprises a delivery device comprising an introducer shaft comprising an atraumatic tip and defining one opening spaced from the atraumatic tip for providing a catheter; one catheter, wherein the catheter comprises an end structure on a delivery end, and means for providing an occlusive material composition into and through the catheter; and an occlusive material composition;

(b) positioning the atraumatic tip of the introducer shaft at or near the fundus of a uterus;

(c) positioning the delivery end of the catheter at or near a uterine cornua such that the end structure is at or near a tubal ostium, wherein the end structure maintains the delivery end in the uterine cornua and aids in localized delivery of the occlusive material composition;

(d) delivering from the catheter an effective amount of the occlusive material composition at or near the ostia of the fallopian tubes; and

(e) occluding one fallopian tube by forming an occlusion with the occlusive material composition within the lumen of the fallopian tube.

2. The method of claim 1 , wherein the fallopian tube is fallopian tube of a human.

3. The method of claim 1 , wherein the occlusive material composition comprises a tissue adhesive.

4. The method of claim 1 , wherein the occlusive material composition is ultrasound visible.

5. The method of claim 4 , wherein the ultrasound visible material comprises microbubbles of air or gas or microparticles of a material that entrap air or gas.

6. The method of claim 3 , wherein the tissue adhesive is cyanoacrylate, polyacrylic acids, polyethylene glycols, modified polyethylene glycols, thrombin, collagen, collagen-based adhesives, fibrin, fibrin glue compositions, gelatin-resorcinol-formaldehyde-glutaraldehye (GRFG) glue, autologous blood in combination with collagen or thrombin, crosslinked albumin adhesives, modified glycosaminoglycans, poly(N-isopropylacrylamide)-based adhesives, alginates, or chitosan or gelatin, crosslinked with carbodiimide or genepin or combinations thereof.

7. The method of claim 1 , wherein the occlusive material composition cures, and the cured composition swells less than 20%.

8. The method of claim 1 , wherein the occlusive material composition is about 20% to about 100% substantially resorbed or degraded in a range of about 30 to about 90 days.

9. The method of claim 1 , wherein the occlusion is maintained by tissue ingrowth or wound healing or similar type response.

10. The method of claim 1 , wherein the occlusive material composition further comprises polymers or particles.

11. The method of claim 10 , wherein the particles are nano- or micro-particles.

12. The method of claim 1 , wherein the occlusive material composition comprises polymers.

13. The method of claim 1 , wherein the occlusive material composition further comprises tissue scarring agents, fibrosis agents, wound healing promoting agents, fertilization inhibitors, contraceptive agents, tissue growth promoters, hormones, polymerization inhibitors, polymerization stabilizers, emulsifying agents, echogenic agents, contrast agents, viscosity-modifying materials, plasticizers, colorants or combinations thereof.

14. The method of claim 1 , wherein the occlusive material composition further comprises a curable carrier for the occlusive materials, a control release agent, tissue scarring agents, wound healing promoting agents, fibrosis agents, fertilization inhibitors, contraceptive agents, tissue growth promoters, hormones, polymerization inhibitors, polymerization stabilizers, emulsifying agents, echogenic agents, contrast agents, viscosity-modifying materials, plasticizers, colorants or combinations thereof.

15. A method for contraception, comprising,

(a) providing a delivery system that delivers an effective amount of an occlusive material composition, wherein the delivery system comprises a delivery device comprising an introducer shaft comprising an atraumatic tip and defining one opening spaced from the atraumatic tip for providing a catheter; one catheter, wherein the catheter comprises an end structure on a delivery end; and means for providing an occlusive material composition into and through the catheter; and an occlusive material composition;

(b) positioning the atraumatic tip of the introducer shaft at or near the fundus of a uterus;

(c) positioning the delivery end of the catheter at or near a uterine cornua such that the end structure is at or near a tubal ostium, wherein the end structure maintains the delivery end in the uterine cornua and aids in localized delivery of the occlusive material composition;

d) delivering an effective amount of the occlusive material composition at or near the tubal ostium such that the occlusive material is provided to a portion of a lumen of a fallopian tube; and

(e) occluding the fallopian tube by forming an occlusion with the occlusive material composition within the lumen of the fallopian tube.

16. The method of claim 15 , wherein the fallopian tube is fallopian tube of a human.

17. The method of claim 15 , wherein the occlusive material composition comprises a tissue adhesive.

18. The method of claim 15 , wherein the occlusive material composition is ultrasound visible.

19. The method of claim 18 , wherein the ultrasound visible material comprises microbubbles of air or gas or microparticles of a material that entrap air or gas.

20. The method of claim 17 , wherein the tissue adhesive is cyanoacrylate, polyacrylic acids, polyethylene glycols, modified polyethylene glycols, thrombin, collagen, collagen-based adhesives, fibrin, fibrin glue compositions, gelatin-resorcinol-formaldehyde-glutaraldehye (GRFG) glue, autologous blood in combination with collagen or thrombin, crosslinked albumin adhesives, modified glycosaminoglycans, poly(N-isopropylacrylamide)-based adhesives, alginates, or chitosan or gelatin, crosslinked with carbodiimide or genepin or combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2015
From: LEE-SEPSICK, KATHY; AZEVEDO, MAX S.; CURRIE, DANIEL S.
To: FEMASYS INC.
Reel/Frame 035243/0970 →
Continuity (6)
Continuation 13285908 · Oct 31, 2011
Continuation 12240738 · Sep 29, 2008
Continuation In Part 11065886 · Feb 24, 2005
Provisional Application 60547491 · Feb 25, 2004
Provisional Application 60587604 · Jul 13, 2004
Related Publication 20130220335A1 · Aug 29, 2013